Business Context and Reporting Period
This Form 8-K reports on the virtual Annual Meeting of Stockholders held by Ionis Pharmaceuticals, Inc. on June 5, 2025. The filing details the outcomes of four proposals submitted to security holders for a vote.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on and approved the following four proposals:
- Proposal 1 (Election of Directors): Four directors were elected to serve until the 2028 Annual Meeting. All nominees received majority affirmative votes, though Joseph Loscalzo received a significant number of "Against" votes (29,465,062) compared to the other nominees.
- Proposal 2 (Say-on-Pay): Stockholders approved the advisory vote on executive compensation with 132,567,606 votes in favor.
- Proposal 3 (Equity Plan Amendment): Stockholders approved an amendment to the 2011 Equity Incentive Plan, increasing the authorized share count by 4,000,000 to a total of 42,500,000 shares. This proposal faced notable opposition with 30,105,665 "Against" votes.
- Proposal 4 (Auditor Ratification): Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the 2025 fiscal year with overwhelming support (144,587,537 "For" votes).
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves strictly as a record of the shareholder vote outcomes.
Investor Verification Checklist
- Verify the specific vote counts for Joseph Loscalzo and the Equity Plan Amendment, as both received higher-than-average opposition relative to other proposals.
- Confirm the updated total authorized shares under the 2011 Equity Incentive Plan (42,500,000) for future dilution analysis.
- Review the definitive proxy statement dated April 25, 2025, referenced in the filing for detailed biographies of the elected directors and executive compensation specifics.